Forbion Capital Partners

Granite Bio is a biotechnology company focused on developing novel monoclonal antibody therapies targeting inflammatory, autoimmune, and fibrotic disorders.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

SynOx Therapeutics is a biopharmaceutical company focused on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Incorporated in 2019, the company is based in Dublin, Ireland.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Beacon Therapeutics is a biotechnology company focused on developing gene therapies for rare retinal diseases that cause blindness. Utilizing its proprietary platform, Beacon aims to restore and improve vision in patients suffering from these debilitating conditions. Currently operating at the clinical stage, the company's primary focus lies within ophthalmology, with the goal of transforming lives by treating severe eye diseases.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

SynOx Therapeutics is a biopharmaceutical company focused on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Incorporated in 2019, the company is based in Dublin, Ireland.

Founded in 2019, Engrail Therapeutics is dedicated to developing and commercializing neuro drugs. Its primary focus is on treating diseases related to the nervous system. The company's flagship compound, ENX-101, is a preclinical modulator of a receptor for GABA, a neurotransmitter in the brain.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Calluna Pharma is a clinical-stage company developing selective antibody therapies targeting immunological diseases. Its pipeline includes novel candidates addressing unmet clinical needs.

Kynexis is focused on developing a precision medicine aimed at treating cognitive impairment associated with schizophrenia. The company employs a human biology-based approach to guide its research, utilizing a causal biomarker strategy to clarify its mechanism of action during clinical development. Additionally, Kynexis incorporates a human genetics approach to identify specific sub-populations of patients who are likely to respond positively to the treatment. Through its innovative methodologies, Kynexis aims to enhance brain function in individuals suffering from schizophrenia, addressing a critical need in mental health care.

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It employs proprietary development and delivery platforms to create optimized therapeutics in a revocable, non-viral format, advancing gene-based therapies with improved safety and controllability. The company integrates capabilities from gene delivery, protein sciences, and clinical translation to address genetically driven diseases and translate scientific advances into clinical options.

Tessellate BIO is a biotechnology company focused on oncology, developing precision therapies that leverage synthetic lethality to treat cancers with significant unmet medical needs. It targets tumors dependent on synthetic lethality mechanisms to create targeted treatments, supported by ongoing research and development in cancer biology and pharmaceutical processes.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

ARMGO Pharma is a biopharmaceutical company focused on developing small-molecule therapeutics to treat debilitating cardiac, skeletal muscle, and neurological disorders. It develops Rycals, calcium release channel stabilizers that act on the ryanodine receptor/calcium release channel on the sarcoplasmic/endoplasmic reticulum to address chronic heart failure, arrhythmias, muscle disorders, cognitive disorders, and related conditions. The company was founded in 2004 and is based in Tarrytown, New York, with an additional office in New York, New York.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Founded in 2017, Anaveon develops biologics that modulate cytokine function to provide therapeutic benefits for cancer patients and those with immune-related disorders. The company focuses on IL-2 complexes that selectively enhance effector T cell functions, acting as effective immune adjuvants.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Founded in 2017, Amphista Therapeutics is a biopharmaceutical company based in Motherwell, UK. It specializes in developing first-in-class cancer therapeutics using targeted protein degradation technology to selectively remove disease-causing proteins.

Oxular is a clinical-stage company developing innovative retinal therapeutics. It focuses on transforming the treatment of retinal diseases by offering tissue-specific drug delivery solutions to address unmet patient needs, such as age-related macular degeneration and diabetic macular edema.

CoviCept Therapeutics is focused on the development of a small molecule that inhibits the replication and spread of RNA viruses.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

SynOx Therapeutics is a biopharmaceutical company focused on developing emactuzumab, a monoclonal antibody targeting CSF-1R, for treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Incorporated in 2019, the company is based in Dublin, Ireland.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. It aims to deliver disease-modifying therapeutics to skeletal, cardiac, and smooth muscle, addressing conditions such as muscular dystrophies and other muscle disorders. The company uses the FORCE platform to create targeted therapeutics with payloads designed to address the disease gene, connected via a linker to an antigen-binding fragment, enabling delivery to muscle tissue and the central nervous system. Its pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. Headquartered in Waltham, Massachusetts.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven neuromuscular diseases. It aims to deliver disease-modifying therapeutics to skeletal, cardiac, and smooth muscle, addressing conditions such as muscular dystrophies and other muscle disorders. The company uses the FORCE platform to create targeted therapeutics with payloads designed to address the disease gene, connected via a linker to an antigen-binding fragment, enabling delivery to muscle tissue and the central nervous system. Its pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. Headquartered in Waltham, Massachusetts.

OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a rapid-onset calcium channel blocker for cardiovascular conditions. The lead product is etripamil, administered as a nasal spray for self-treatment of episodes of paroxysmal supraventricular tachycardia, with ongoing Phase III studies in the United States and Canada. The company is also advancing development for other cardiovascular indications, including atrial fibrillation and angina, with a Phase II program for atrial fibrillation with rapid ventricular response. Founded in 2003, Milestone is headquartered in Montreal.

Gotham Therapeutics Corp. is a biotechnology company based in New York, founded in 2017, that focuses on developing innovative treatments for patients with cancers, autoimmune disorders, and neurodegenerative diseases. The company specializes in a novel class of drugs that target the machinery of epitranscriptomics, which involves altering the activity of proteins that modify messenger ribonucleic acid (mRNA). By utilizing small molecules that inhibit the transcription of proteins through modifications to mRNA, Gotham Therapeutics aims to enhance treatment options and improve outcomes for individuals affected by serious health conditions.

KaNDy Therapeutics is a biopharmaceutical company specializing in the development of non-hormonal treatments for various symptoms associated with menopause, including hot flashes and nighttime awakenings. Founded in 2017 and based in Stevenage, United Kingdom, the company focuses on providing effective therapies for moderate to severe post-menopausal vasomotor symptoms. Its lead product, NT-814, addresses chronic debilitating conditions related to female sex hormones, offering a viable alternative for patients seeking relief without hormonal interventions. As a subsidiary of Bayer Aktiengesellschaft, KaNDy Therapeutics aims to improve the quality of life for women experiencing hormone-related challenges.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a rapid-onset calcium channel blocker for cardiovascular conditions. The lead product is etripamil, administered as a nasal spray for self-treatment of episodes of paroxysmal supraventricular tachycardia, with ongoing Phase III studies in the United States and Canada. The company is also advancing development for other cardiovascular indications, including atrial fibrillation and angina, with a Phase II program for atrial fibrillation with rapid ventricular response. Founded in 2003, Milestone is headquartered in Montreal.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Allecra Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat Gram-negative multi-drug resistant bacterial infections. Founded in 2013 and based in Weil am Rhein, Germany, it develops beta-lactamase inhibitors to counter resistance mechanisms in hard-to-treat bacteria, particularly those linked with hospital-acquired infections. Its beta-lactamase inhibitor program aims to restore the activity of beta-lactam antibiotics against resistant pathogens, with a beta-lactamase inhibitor in Phase 2 development. The company operates in the BioValley Life Sciences region of the Upper Rhine valley, spanning parts of Switzerland, Germany, and France, to advance research and clinical development and improve outcomes for patients and healthcare systems facing resistant infections.

Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics for inflammatory and fibrotic diseases. Established in 2014, the company operates out of offices in Cambridge, United Kingdom, and San Diego, California. Akarna's lead program centers on a non-bile acid FXR agonist, which aims to provide a best-in-class therapeutic option for treating nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease with no currently approved treatments. At present, the lead candidate is undergoing preclinical studies, including IND-enabling toxicology and safety pharmacology assessments, with plans to initiate first-in-human trials.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Ario Pharma Ltd is engaged in the development of therapeutic drugs aimed at treating respiratory conditions. The company is focused on evaluating the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, through Phase 2 clinical trials. In addition to its respiratory focus, Ario Pharma is also developing a range of small-molecule TRPV1 antagonists that target neuropathic and inflammatory pain. The company is backed by a highly experienced development team and is supported by leading experts in respiratory disease, ensuring a robust approach to drug development.

Argos Therapeutics is a biotechnology company specializing in developing immunotherapy treatments for cancer and infectious diseases. It focuses on personalized immunotherapies using its proprietary Arcelis technology platform, with product candidates including rocapuldencel-T for metastatic renal cell carcinoma and AGS-004 for HIV.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

uniQure is a pioneering gene therapy company recognized for developing the first gene therapy product to receive regulatory approval in the European Union. Its initial product, Glybera, was authorized in October 2012 for treating patients with lipoprotein lipase deficiency, a rare and severe metabolic disorder. uniQure specializes in creating innovative gene therapies that offer long-term and potentially curative benefits for genetic and acquired diseases. The company utilizes a modular technology platform and a proprietary manufacturing process to develop its treatments. Currently, uniQure is expanding its pipeline of adeno-associated virus (AAV)-based gene therapies, focusing on conditions such as hemophilia, Huntington's disease, and cardiovascular diseases through collaborations, including one with Bristol Myers Squibb. While the company initially targets orphan diseases, it also aims to address chronic and degenerative diseases affecting larger populations.

Allecra Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat Gram-negative multi-drug resistant bacterial infections. Founded in 2013 and based in Weil am Rhein, Germany, it develops beta-lactamase inhibitors to counter resistance mechanisms in hard-to-treat bacteria, particularly those linked with hospital-acquired infections. Its beta-lactamase inhibitor program aims to restore the activity of beta-lactam antibiotics against resistant pathogens, with a beta-lactamase inhibitor in Phase 2 development. The company operates in the BioValley Life Sciences region of the Upper Rhine valley, spanning parts of Switzerland, Germany, and France, to advance research and clinical development and improve outcomes for patients and healthcare systems facing resistant infections.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapeutics for rare fibrotic diseases and retinal fibrovascular conditions. The company targets conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein designed for intravenous injection, and PRM-167, a variant formulated for intravitreal delivery. Promedior employs a novel drug discovery platform that aims to regulate monocyte-derived cell populations, which are critical in inflammatory, fibrotic, and autoimmune diseases. By specifically addressing these cells at the injury site, Promedior seeks to treat the underlying causes of immune system dysregulation, promote tissue healing, and minimize systemic side effects associated with traditional therapies. The company's commitment to addressing severe and challenging conditions positions it as a significant player in the biopharmaceutical landscape.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Argos Therapeutics is a biotechnology company specializing in developing immunotherapy treatments for cancer and infectious diseases. It focuses on personalized immunotherapies using its proprietary Arcelis technology platform, with product candidates including rocapuldencel-T for metastatic renal cell carcinoma and AGS-004 for HIV.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapeutics for rare fibrotic diseases and retinal fibrovascular conditions. The company targets conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein designed for intravenous injection, and PRM-167, a variant formulated for intravitreal delivery. Promedior employs a novel drug discovery platform that aims to regulate monocyte-derived cell populations, which are critical in inflammatory, fibrotic, and autoimmune diseases. By specifically addressing these cells at the injury site, Promedior seeks to treat the underlying causes of immune system dysregulation, promote tissue healing, and minimize systemic side effects associated with traditional therapies. The company's commitment to addressing severe and challenging conditions positions it as a significant player in the biopharmaceutical landscape.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapeutics for rare fibrotic diseases and retinal fibrovascular conditions. The company targets conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein designed for intravenous injection, and PRM-167, a variant formulated for intravitreal delivery. Promedior employs a novel drug discovery platform that aims to regulate monocyte-derived cell populations, which are critical in inflammatory, fibrotic, and autoimmune diseases. By specifically addressing these cells at the injury site, Promedior seeks to treat the underlying causes of immune system dysregulation, promote tissue healing, and minimize systemic side effects associated with traditional therapies. The company's commitment to addressing severe and challenging conditions positions it as a significant player in the biopharmaceutical landscape.

PanGenetics B.V., based in Utrecht, Netherlands, specializes in the development of monoclonal antibodies aimed at treating immune-mediated diseases. The company focuses on advancing antibodies from late-stage research to clinical proof of concept, utilizing a lean business model that outsources manufacturing and clinical development to specialized providers. Among its clinical programs is PG110, along with PG102, a CD40 antagonist currently undergoing evaluation in a clinical study for patients with psoriatic arthritis. Additionally, PanGenetics employs an in-licensing model to expand its portfolio of antibody-based therapeutic products. The company's strategic approach allows it to concentrate on its core competencies while leveraging external expertise for other critical functions.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Acadia Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs targeting unmet medical needs in central nervous system disorders. Its primary product, NUPLAZID (pimavanserin), treats hallucinations and delusions associated with Parkinson's disease psychosis.

Impella CardioSystems AG, located in Aachen, Germany, specializes in the development, manufacturing, and marketing of minimally invasive cardiovascular support systems designed for various cardiology and coronary surgery applications. The company produces intracorporeal micro blood pumps, which are utilized to support patients undergoing these medical procedures. With a robust portfolio of over 30 European and international patents protecting its innovative technology, Impella employs a team of 50 individuals. For the past two years, the company has collaborated with Accelerated Technologies, Inc., a medical device accelerator based in Hackensack, New Jersey, to enhance its growth and development in the medical device sector.